Q-omics provides the consensus-scored MIR3684 profile across patient tissues and cancer cell-line models. MIR3684 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR3684 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR3684 RNA expression shows 7,772 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, BRCA, and LSCC as cancer lineages where MIR3684 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3684 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3684 survival associations across molecular data types. MIR3684 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3684 RNA expression–survival associations across cancer types. High MIR3684 expression shows unfavorable associations in LIHC, UVM, THCA, ACC and CHOL, but favorable associations in CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR3684 RNA expression.
This table summarizes MIR3684 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3684. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3684 shows higher tumor expression in BRCA and LUSC. The BRCA box plot shows higher MIR3684 RNA expression in tumor versus normal tissue (log2 FC = +0.171, t-test p = .022).
This table shows molecular features associated with MIR3684 in patient tissues and cancer cell lines. In patient samples, MIR3684 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
